Why Lineage Cell Therapeutics Stock Is Soaring Today

This article was originally published on this site

© Provided by The Motley Fool Why Lineage Cell Therapeutics Stock Is Soaring Today

What happened

Shares of Lineage Cell Therapeutics (NYSEMKT: LCTX) were soaring by 19.4% as of 12:01 p.m. EDT on Tuesday. The big gain came after the company announced positive news from a phase 1/2a study evaluating OpRegen in treating dry age-related macular degeneration (AMD).

So what 

Lineage Cell Therapeutics reported it observed restoration of retinal tissue in two additional patients in its study of OpRegen. The company reported its first case of retinal restoration last year. CEO Brian Culley said, “To our knowledge, these three patients represent the only examples of an experimental treatment for dry AMD demonstrating a reduction, rather than attenuating further expansion, of an area of atrophy in humans.”

© Getty Images Letters spelling AMD next to a plastic eyeball with an eye chart in the background.

The news is so encouraging that Lineage filed a Patent Cooperation Treaty (PCT) patent application for the restoration of the anatomy and/or functionality of diseased retinas. This filing enables the company to seek patent protection in multiple countries simultaneously. If Lineage receives approval for its patent application, it would have intellectual property protection at least through May 24, 2041.

Load Error

Now what

Lineage now plans to discuss its detailed findings from the study of OpRegen with external therapeutic experts. The company also will evaluate its pathways for regulatory approval of the allogeneic retinal pigment epithelium (RPE) cell transplant therapy. With three of four patients who received OpRegen so far experiencing retinal tissue restoration, the prospects for this biotech stock appear bright.

SPONSORED:

10 stocks we like better than Lineage Cell Therapeutics, Inc.

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Lineage Cell Therapeutics, Inc. wasn’t one of them! That’s right — they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of May 11, 2021

 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Continue Reading